Drug-Target Information
Drug Name Target Name Drug Type Target Type Source Drug MeSHID Interaction Score Drug Status Target Action
gemtuzumab ozogamicin myeloid cell surface antigen cd33 biotech Successful target TTD , drugbank , DGIDB Relapse[MeSHID:D012008]
Leukemia
Myelocytic
Acute[MeSHID:D015470]
Disruptive
Impulse Control
and Conduct Disorders[MeSHID:D007174]		 5.3 approved,investigational antibody
gemtuzumab ozogamicin myeloid cell surface antigen cd33 biotech Successful target TTD , drugbank , DGIDB Relapse[MeSHID:D012008]
Leukemia
Myelocytic
Acute[MeSHID:D015470]
Disruptive
Impulse Control
and Conduct Disorders[MeSHID:D007174]		 NA approved,investigational antibody
gemtuzumab ozogamicin high affinity immunoglobulin gamma fc receptor i biotech NA drugbank Relapse[MeSHID:D012008]
Leukemia
Myelocytic
Acute[MeSHID:D015470]
Disruptive
Impulse Control
and Conduct Disorders[MeSHID:D007174]		 NA approved,investigational unknown
gemtuzumab ozogamicin low affinity immunoglobulin gamma fc region receptor iii-a biotech NA drugbank Relapse[MeSHID:D012008]
Leukemia
Myelocytic
Acute[MeSHID:D015470]
Disruptive
Impulse Control
and Conduct Disorders[MeSHID:D007174]		 NA approved,investigational unknown
gemtuzumab ozogamicin low affinity immunoglobulin gamma fc region receptor iii-b biotech NA drugbank Relapse[MeSHID:D012008]
Leukemia
Myelocytic
Acute[MeSHID:D015470]
Disruptive
Impulse Control
and Conduct Disorders[MeSHID:D007174]		 NA approved,investigational unknown
click here to return to the previous page